Literature DB >> 17981789

A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.

Giuliana Salvatore1, Tito Claudio Nappi, Paolo Salerno, Yuan Jiang, Corrado Garbi, Clara Ugolini, Paolo Miccoli, Fulvio Basolo, Maria Domenica Castellone, Anna Maria Cirafici, Rosa Marina Melillo, Alfredo Fusco, Michael L Bittner, Massimo Santoro.   

Abstract

Here, we show that the anaplastic thyroid carcinoma (ATC) features the up-regulation of a set of genes involved in the control of cell cycle progression and chromosome segregation. This phenotype differentiates ATC from normal tissue and from well-differentiated papillary thyroid carcinoma. Transcriptional promoters of the ATC up-regulated genes are characterized by a modular organization featuring binding sites for E2F and NF-Y transcription factors and cell cycle-dependent element (CDE)/cell cycle gene homology region (CHR) cis-regulatory elements. Two protein kinases involved in cell cycle regulation, namely, Polo-like kinase 1 (PLK1) and T cell tyrosine kinase (TTK), are part of the gene set that is up-regulated in ATC. Adoptive overexpression of p53, p21 (CIP1/WAF1), and E2F4 down-regulated transcription from the PLK1 and TTK promoters in ATC cells, suggesting that these genes might be under the negative control of tumor suppressors of the p53 and pRB families. ATC, but not normal thyroid, cells depended on PLK1 for survival. RNAi-mediated PLK1 knockdown caused cell cycle arrest associated with 4N DNA content and massive mitotic cell death. Thus, thyroid cell anaplastic transformation is accompanied by the overexpression of a cell proliferation/genetic instability-related gene cluster that includes PLK1 kinase, which is a potential molecular target for ATC treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981789     DOI: 10.1158/0008-5472.CAN-07-1887

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  78 in total

1.  Cellular abundance of Mps1 and the role of its carboxyl terminal tail in substrate recruitment.

Authors:  Tingting Sun; Xiaomei Yang; Wei Wang; Xiaojuan Zhang; Quanbin Xu; Songcheng Zhu; Robert Kuchta; Guanjun Chen; Xuedong Liu
Journal:  J Biol Chem       Date:  2010-09-30       Impact factor: 5.157

2.  Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.

Authors:  Naoki Oishi; Tetsuo Kondo; Aya Ebina; Yukiko Sato; Junko Akaishi; Rumi Hino; Noriko Yamamoto; Kunio Mochizuki; Tadao Nakazawa; Hiroshi Yokomichi; Koichi Ito; Yuichi Ishikawa; Ryohei Katoh
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

Review 3.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

4.  E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, Is Reciprocally Regulated by Wild-type and Gain-of-Function Mutant p53.

Authors:  Swati Bajaj; Sk Kayum Alam; Kumar Singha Roy; Arindam Datta; Somsubhra Nath; Susanta Roychoudhury
Journal:  J Biol Chem       Date:  2016-04-28       Impact factor: 5.157

5.  Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.

Authors:  Naoyoshi Onoda; Masanori Nakamura; Naoki Aomatsu; Satoru Noda; Shinichiro Kashiwagi; Kosei Hirakawa
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

6.  A transcriptional and metabolic signature of primary aneuploidy is present in chromosomally unstable cancer cells and informs clinical prognosis.

Authors:  Jason M Sheltzer
Journal:  Cancer Res       Date:  2013-09-16       Impact factor: 12.701

Review 7.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

8.  EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.

Authors:  Ranju Ralhan; Jun Cao; Terence Lim; Christina Macmillan; Jeremy L Freeman; Paul G Walfish
Journal:  BMC Cancer       Date:  2010-06-25       Impact factor: 4.430

Review 9.  Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?

Authors:  D Dolfini; R Mantovani
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

Review 10.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.